Pre-Emptive Rituximab Treatment for Epstein-Barr Virus (EBV) Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): High Incidence of Infections and Delayed Immune Reconstitution

被引：0
|
作者：
Petropoulou, Anna D. [1 ]
Porcher, Raphael [1 ]
de Latour, Regis Peffault [1 ]
Xhaard, Alienor [1 ]
Ribaud, Patricia [1 ]
Socie, Gerard [1 ]
Robin, Marie [1 ]
机构：
[1] St Louis Hosp, Paris, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：950 / 951
页数：2
相关论文
共 50 条
  • [1] Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation
    Kobayashi, Shogo
    Sano, Hideki
    Mochizuki, Kazuhiro
    Ohara, Yoshihiro
    Takahashi, Nobuhisa
    Ohto, Hitoshi
    Kikuta, Atsushi
    PEDIATRICS INTERNATIONAL, 2017, 59 (09) : 973 - 978
  • [2] Impact of Pre-Emptive Rituximab Treatment for Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Longitudinal Study of 110 Patients
    Stocker, Nicolas
    Labopin, Myriam
    Boussen, Ines
    Lamarthee, Baptiste
    Malard, Florent
    Bonnin, Agnes
    Marechal, Vincent
    Amiel, Corinne
    Quignon, Frederique
    Gozlan, Joel
    Battipaglia, Giorgia
    Dulery, Remy
    Giannotti, Federica
    Ruggeri, Annalisa
    Gaugler, Beatrice
    Mohty, Mohamad
    Brissot, Eolia
    BLOOD, 2017, 130
  • [3] Pre-emptive treatment with rituximab for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation: a safety and efficacy study
    Ganguly, S.
    DuBois, L.
    Divine, C.
    Aljitawi, O.
    Abhyankar, S.
    McGuirk, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S225 - S225
  • [4] Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
    Jain, Tania
    Kung, Shu Ting
    Kosiorek, Heidi
    Shah, Vishal
    Khera, Nandita
    Leis, Jose
    Noel, Pierre
    Palmer, Jeanne
    Slack, James L.
    Sproat, Lisa Z.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S279 - S280
  • [5] Increased infection rate after pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation
    Petropoulou, A.
    Porcher, R.
    de Latour, R. Peffault
    Xhaard, A.
    Ribaud, P.
    Rodriguez-Otero, P.
    Toubert, A.
    Carmagnat, M.
    Socie, G.
    Robin, M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S80 - S81
  • [6] Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
    Stocker, Nicolas
    Labopin, Myriam
    Boussen, Ines
    Paccoud, Olivier
    Bonnin, Agnes
    Malard, Florent
    Amiel, Corinne
    Gozlan, Joel
    Battipaglia, Giorgia
    Dulery, Remy
    Giannotti, Federica
    Ruggeri, Annalisa
    Gaugler, Beatrice
    Mohty, Mohamad
    Brissot, Eolia
    BONE MARROW TRANSPLANTATION, 2020, 55 (03) : 586 - 594
  • [7] Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
    Nicolas Stocker
    Myriam Labopin
    Inès Boussen
    Olivier Paccoud
    Agnès Bonnin
    Florent Malard
    Corinne Amiel
    Joël Gozlan
    Giorgia Battipaglia
    Rémy Duléry
    Federica Giannotti
    Annalisa Ruggeri
    Béatrice Gaugler
    Mohamad Mohty
    Eolia Brissot
    Bone Marrow Transplantation, 2020, 55 : 586 - 594
  • [8] Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation
    Gruhn, B
    Meerbach, A
    Häfer, R
    Zell, R
    Wutzler, P
    Zintl, F
    BONE MARROW TRANSPLANTATION, 2003, 31 (11) : 1023 - 1025
  • [9] Pre-emptive therapy of Epstein-Barr virus (EBV) reactivation after allogeneic hematopoietic stem cell transplant (HSCT) with four courses of i.v. cydofovir: A single centre experience.
    Dominietto, A
    Tedone, E
    Soracco, M
    Bregante, S
    Di Grazia, C
    Lamparelli, T
    Raiola, AM
    Van Lint, MT
    Gualandi, F
    Frassoni, F
    Bacigalupo, A
    BLOOD, 2002, 100 (11) : 630A - 630A
  • [10] Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
    Papalexandri, Apostolia
    Gavriilaki, Eleni
    Vardi, Anna
    Baldoumi, Eirini
    Demosthenous, Christos
    Konstantinou, Natasa
    Touloumenidou, Tasoula
    Zerva, Panagiota
    Kika, Fotini
    Paleta, Angeliki
    Iskas, Michalis
    Batsis, Ioannis
    Mallouri, Despina
    Yannaki, Evangelia
    Sakellari, Ioanna
    Anagnostopoulos, Achilles
    BLOOD, 2020, 136
12345